Health Source (600380.SH): JKN2301 dry suspension approved for clinical trials

Zhitongcaijing · 06/19/2025 09:17

Zhitong Finance App News, Health Yuan (600380.SH) issued an announcement. Recently, the company received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration (hereinafter referred to as the State Drug Administration), which approved the company's JKN2301 dry suspension to carry out clinical trials.

The JKN2301 dry suspension approved for clinical trials is an innovative drug developed with the patented compound mapasisavir. It is suitable for children under 2 to 12 years of age with simple influenza A and B influenza. The JKN2301 dry suspension is developed for children. It can flexibly adjust the dosage according to the child's body weight, improve children's medication compliance, adapt to children's medication needs, and fill clinical needs in the field of pediatric influenza treatment.